The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Exploring CD83 CARs as an approach to overcome CD19 antigen loss in B-cell malignancies
Marco Davila, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, highlights the development of CD83-directed CAR T-cells as a strategy to overcome CD19 antigen loss in relapsed B-cell malignancies following CD19-targeted therapy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
CD83 CAR T-cells are something we developed in the lab a few years ago. It is a novel target for immunotherapy. We just opened a first-in-human phase one trial for patients with acute myeloid leukemia that have CD83 positive disease. But we looked to see what other cancers might express it and it turns out B-cell malignancies also express high levels of CD83. And so we are developing this CAR for patients that have been treated with the CD19 CAR T-cell technology, but have relapsed...
CD83 CAR T-cells are something we developed in the lab a few years ago. It is a novel target for immunotherapy. We just opened a first-in-human phase one trial for patients with acute myeloid leukemia that have CD83 positive disease. But we looked to see what other cancers might express it and it turns out B-cell malignancies also express high levels of CD83. And so we are developing this CAR for patients that have been treated with the CD19 CAR T-cell technology, but have relapsed. And so we did some preclinical studies to show that patients that are in vitro and in vivo, when you treat with a CD19 CAR and that CD19 antigen is lost, you can use a CD83 CAR T cell and it works completely fine. So based on this information, we’re going to be developing a clinical trial to open at Roswell Park in a year or two.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
